Why the study?
The authors aimed to evaluate the clinical characteristics and outcomes of patients admitted with acute pulmonary embolism at a single center over a 5-year period.
Does systemic thrombolysis improve outcomes or increase bleeding in patients with acute pulmonary embolism?
Does systemic thrombolysis improve outcomes or increase bleeding in patients with acute pulmonary embolism?
Non-guideline use of systemic thrombolysis in acute pulmonary embolism is associated with significantly increased bleeding risk despite improvements in pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Thrombolysis was associated with higher bleeding despite pulmonary hypertension improvement in acute PE; leaves open net clinical benefit pending randomized trials.
Aim and Methods: We aimed to study the clinical data and outcome of patients admitted in our center with acute pulmonary embolism (PE) over a 5-year period from May 2013 to April 2018. The main outcome data included were: in - hospital bleeding, in - hospital right ventricular (RV) function improvement, pulmonary arterial hypertension improvement, duration of hospital stay, and 30- and 90-day mortality. Results: A total of 114 (69 m, 55 f) patients with the mean age of 55 ± 15 years were included. Patients who had involvement of central pulmonary trunk called as “Central PE” group ( n = 82) and others as “Peripheral PE” group ( n = 32). There were more women in the peripheral PE group (53.1% vs. 34.1%, P = 0.05), while RBBB (22% vs. 3.1%, P = 0.02) and RV dysfunction (59.8% vs. 25%, P = 0.002) were noted more in the central PE group. Systemic thrombolysis was done in 53 patients (49 central, 4 peripheral), of which only 3 had hypotension and 28 patients were in the Intermediate-high risk group. The overall inhospital, 30-day, and 90-day mortalities were 3.6, 13.2, and 22.8%, respectively. Bleeding was significantly higher in the thrombolysis group compared to the nonthrombolysis group (18.9% vs. 0, P = 0.0003). However, improvement in pulmonary hypertension was noted more in thrombolysis group compared to nonthrombolytic group (49% vs. 21.2%, P = 0.01). Conclusion: This retrospective data from a tertiary center in South India showed that short- and mid-term mortality of patients with PE still remains high. The high nonguideline use of thrombolysis has been reflected in the increased bleeding noted in our study.
No takes yet. Share an insight, caveat, or question.
Showkathali et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: